ELV — Evaluation History

Elevance Health, Inc.
Deterministic Evaluations last 3 months
1 records
Date Strategy Price Decision Conf Tech Macro Sector Earn Regime Rationale
11 Mar 2026 SectorRotationLLM $0.00 BUY 78% 0 0 0 0 Neutral [Healthcare] ELV has recently reclaimed its 200-day moving average after a multi-month base consolidation near the $450–$470 range, with volume expanding on recent up days suggesting early institutional accumulation. Catalyst: Q1 2026 earnings report (expected mid-April) could serve as a significant re-rating event if medical loss ratios continue to improve; additionally, any favorable CMS Medicare Advantage rate announcements for 2027 would act as a near-term positive surprise.
AI Evaluations last 3 months
0 records

No AI evaluations in the last 3 months.

An error has occurred. This application may no longer respond until reloaded. Reload 🗙